Moderna in EC deal over COVID-19 vaccine

24 August 2020

US biotech Moderna (Nasdaq: MRNA) has concluded advanced exploratory talks with the European Commission (EC) to supply 80 million doses of mRNA-1273, its vaccine candidate against COVID-19.

The potential purchase agreement with the EC of 80 million doses provides for an option for member states to purchase an additional 80 million doses, for a total of up to 160 million doses.

The Phase III study of mRNA-1273 began on July 27 and enrollment of around 30,000 participants is on track to complete in September.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK